CBRE Group Interest Paid decreased by 19.7% to $98.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.9%, from $102.00M to $98.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 81.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.13M | $12.92M | $11.87M | $12.83M | $14.92M | $41.13M | $20.12M | $39.00M | $52.00M | $37.00M | $63.00M | $100.00M | $70.00M | $137.00M | $89.00M | $102.00M | $124.00M | $100.00M | $122.00M | $98.00M |
| QoQ Change | — | >999% | -8.1% | +8.1% | +16.3% | +175.7% | -51.1% | +93.8% | +33.3% | -28.8% | +70.3% | +58.7% | -30.0% | +95.7% | -35.0% | +14.6% | +21.6% | -19.4% | +22.0% | -19.7% |
| YoY Change | — | — | — | — | >999% | +218.4% | +69.5% | +204.1% | +248.5% | -10.0% | +213.1% | +156.4% | +34.6% | +270.3% | +41.3% | +2.0% | +77.1% | -27.0% | +37.1% | -3.9% |